Susquehanna International Group
ALGS icon

Susquehanna International Group’s Aligos Therapeutics ALGS Stock Holding History

Susquehanna International Group’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,107
Closed -$99K – 12231
2025
Q3 		$99K Buy
+10,107
New +$92.4K ﹤0.01% 11570
2025
Q2 		– Sell
-40,612
Closed -$335K – 12574
2025
Q1 		$335K Buy
+40,612
New +$890K ﹤0.01% 9827
2023
Q2 		– Sell
-984
Closed -$21.5K – 11974
2023
Q1 		$21.5K Buy
+984
New +$37.6K ﹤0.01% 12025
2022
Q3 		– Sell
-641
Closed -$19K – 13092
2022
Q2 		$19K Buy
+641
New +$21.8K ﹤0.01% 12373
2021
Q2 		– Sell
-367
Closed -$209K – 12494
2021
Q1 		$209K Buy
+367
New +$244K ﹤0.01% 11348

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Susquehanna International Group's ALGS Position: Q4 2025 in Review

Susquehanna International Group sold out of Aligos Therapeutics (ALGS) in Q4 2025, closing a stake of 10,107 shares — an estimated $99K sold.

Susquehanna International Group first reported a position in ALGS in Q1 2021 and held it in 5 quarters. The position peaked at $335K in Q1 2025. 40 funds tracked by Wall St. Rank hold ALGS as of Q4 2025.

  • Susquehanna International Group reported no remaining Aligos Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Susquehanna International Group sold 10,107 Aligos Therapeutics shares in Q4 2025, an estimated $99K.
  • Susquehanna International Group first reported a position in Aligos Therapeutics in Q1 2021 and held it in 5 quarters.
  • Susquehanna International Group's Aligos Therapeutics position peaked at $335K in Q1 2025.
  • 40 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q4 2025.

Based on Susquehanna International Group's 13F filing for Q4 2025, filed 17 Feb 2026.